Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate
LETTER TO THE EDITOR|Updated:2023-03-20
|
Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate
Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate
解放军医学杂志(英文版)2022年9卷第6期 页码:754-756
Affiliations:
1.Department of Urology, Fudan University Shanghai Cancer Center, 270 Dong’an Road, Shanghai 200032, China
2.Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
3.Department of Urology, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, China
Author bio:
* guowenlin@urocancer.org;
dwyeli@163.com
Funds:
the National Natural Science Foundation of China(81902574);the Shanghai Basic Research Program(19JC1411600);the Shanghai Natural Science Foundation(21ZR1414500);the Shanghai Sailing Program(19YF1409800)
Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate[J]. 解放军医学杂志(英文版), 2022,9(6):754-756.
Wang JY, Yu GP, Li L, Lin GW, Ye DW. Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate. Mil Med Res. 2022;9(1):5.
Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate[J]. 解放军医学杂志(英文版), 2022,9(6):754-756. DOI: 10.1186/s40779-021-00364-x.
Wang JY, Yu GP, Li L, Lin GW, Ye DW. Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate. Mil Med Res. 2022;9(1):5. DOI: 10.1186/s40779-021-00364-x.
Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate
Bray F , Ferlay J , Soerjomataram I , Siegel RL , Torre LA , Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries . CA Cancer J Clin . 2018 ; 68 ( 6 ): 394 - 424 .
Fizazi K , Scher HI , Molina A , Logothetis CJ , Chi KN , Jones RJ , et al . Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study . Lancet Oncol . 2012 ; 13 ( 10 ): 983 - 92 .
de Bono JS , Logothetis CJ , Molina A , Fizazi K , North S , Chu L , et al . Abiraterone and increased survival in metastatic prostate cancer . N Engl J Med . 2011 ; 364 ( 21 ): 1995 - 2005 .
Scher HI , Morris MJ , Stadler WM , Higano C , Basch E , Fizazi K , et al . Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3 . J Clin Oncol . 2016 ; 34 ( 12 ): 1402 - 18 .
Rescigno P , Lorente D , Bianchini D , Ferraldeschi R , Kolinsky MP , Sideris S , et al . Prostate-specific antigen decline after 4 weeks of treatment with abiraterone acetate and overall survival in patients with metastatic castration-resistant prostate cancer . Eur Urol . 2016 ; 70 ( 5 ): 724 - 31 .
The trial reading is over, you can activate your VIP account to continue reading.
Standardizing the classification of gastric cancer patients with limited and adequate number of retrieved lymph nodes: an externally validated approach using real-world data
钢拱桥极限承载力的综合三因素检算方法
长大货物列车空气管系3维充气模型的数值仿真
地铁高架槽形梁足尺模型破坏试验与空间分析研究
二取二制式计算机联锁系统中的通信技术
相关作者
Wei Wang
Yu-Jie Yang
Ri-Hong Zhang
Jing-Yu Deng
Zhe Sun
Sharvesh Raj Seeruttun
Zhen-Ning Wang
Hui-Mian Xu
相关机构
Department of Gastric Surgery, Sun Yat-sen University Cancer Center
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
Department of Gastric Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital
Department of Surgical Oncology, the First Hospital of China Medical University